EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial

Tian Hui Zou, Qin Yan Gao iD, Si De Liu, Yan Qing Li iD, Xiang Jun Meng, Guo Xin Zhang, Zi Bin Tian, Xiao Ping Zou, Song He, Xiao Hua Hou, Rong Lin, Jing Nan Li iD und 14 weitere

Journal of Digestive Diseases · 2024-01 · 25 (1) · 27-35

DOI: 10.1111/1751-2980.13251 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Digestive Diseases, online erschienen am 11.02.2024. Verfasst von Tian Hui Zou und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory of Systems Medicine for Cancer, NHC Key La…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Gastritis, Atrophic, Helicobacter Infections, Precancerous Conditions. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the clinical potential and safety of Moluodan to reverse gastric precancerous lesions.

Methods

Patients aged 18–70 years diagnosed with moderate‐to‐severe atrophy and/or moderate‐to‐severe intestinal metaplasia, with or without low‐grade dysplasia, and negative for Helicobacter pylori were recruited in this randomized, double‐blind, parallel‐controlled trial. The primary outcome was the improvement of global histological diagnosis at 1‐year follow‐up endoscopy using the operative link for gastritis assessment, the operative link for gastric intestinal metaplasia assessment, and the disappearance rate of dysplasia.

Results

Between November 3, 2017 and January 27, 2021, 166 subjects were randomly assigned to the Moluodan group, 168 to the folic acid group, 84 to the combination group, and 84 to the high‐dose Moluodan group. The improvement in global histological diagnosis was achieved in 60 (39.5%) subjects receiving Moluodan, 59 (37.8%) receiving folic acid, 26 (32.1%) receiving the combined drugs, and 36 (47.4%) receiving high‐dose Moluodan. Moluodan was non‐inferior to folic acid (95% confidence interval: −9.2 to 12.5; P = 0.02). High‐dose Moluodan had a trend for better protective efficacy, though there was no statistical significance. The disappearance rate of dysplasia was 82.8% in the Moluodan group, which was superior to folic acid (53.9%; P = 0.006). No drug‐related serious adverse events were observed.

Conclusions

One pack of Moluodan three times daily for 1 year was safe and effective in reversing gastric precancerous lesions, especially dysplasia. Doubling its dose showed a better efficacy trend.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsGastritis, AtrophicHelicobacter InfectionsPrecancerous ConditionsHelicobacter pyloriDrugs, Chinese HerbalHumansMetaplasiaFolic AcidGastric Mucosa

Stichwörter der Autor:innen

atrophychemopreventiondysplasiagastric neoplasmsintestinal metaplasia

Substanzen

moluodanFolic AcidDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Disease, Renji Hospital, School of Medicine, Sha…
  • Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
  • Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
  • Department of Gastroenterology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Gut Microecology and Associated Major Diseases Research; Center for Digestiv…
  • Department of Gastroenterology and Hepatology, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China.
  • Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.

ORCID-Profile: Qin Yan Gao, Yan Qing Li, Jing Nan Li, Qian Cao, Ying Xuan Chen, Jing-Yuan Fang

Zitieren

APA

Zou, T. H., Gao, Q. Y., Liu, S., Li, Y. Q., Meng, X. J., Zhang, G. X., Tian, Z. B., Zou, X. P., He, S., Hou, X. H., Lin, R., Li, J. N., Zhou, Z. Y., Li, Y., Wang, M. C., Wang, B. M., Tian, A., Chen, S. J., Cao, Q., …, & Fang, J. Y. (2024). Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial. Journal of Digestive Diseases, 25(1), 27-35. https://doi.org/10.1111/1751-2980.13251

Vancouver

Zou TH, Gao QY, Liu S, Li YQ, Meng XJ, Zhang GX, et al. Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial. Journal of Digestive Diseases. 2024;25(1):27-35. doi:10.1111/1751-2980.13251

BibTeX
@article{Zou2024,
  author = {Zou, Tian Hui and Gao, Qin Yan and Liu, Si De and Li, Yan Qing and Meng, Xiang Jun and Zhang, Guo Xin and Tian, Zi Bin and Zou, Xiao Ping and He, Song and Hou, Xiao Hua and Lin, Rong and Li, Jing Nan and Zhou, Zhong Yin and Li, Yan and Wang, Meng Chun and Wang, Bang Mao and Tian, De An and Chen, Shu Jie and Cao, Qian and Li, Liang Ping and Wang, Zhi Rong and Shen, Xi Zhong and Liu, Bing Rong and Yan, Xiao Yan and Chen, Ying Xuan and Fang, Jing-Yuan},
  title = {Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial},
  journal = {Journal of Digestive Diseases},
  year = {2024},
  volume = {25},
  number = {1},
  pages = {27--35},
  doi = {10.1111/1751-2980.13251}
}
Kostenlos starten →